MammaPrint is a gene expression profiling test (also referred to as a ‘genomic test’, ‘genomic assay’, or ‘gene expression profiling test’) that reveals the distinct underlying biology of an early-stage tumor to determine its risk of spreading. This FDA-cleared and CE-marked gene expression profiling test assesses a woman’s risk of distant metastasis and based on clinical evidence, provides critical answers that inform the future of woman’s treatment plans at the point of diagnosis, including the timing and benefit to chemotherapy and endocrine therapy. MammaPrint listens to the signals from 70 key genes in a woman’s tumor and based on clinical evidence, stratifies recurrence risk within four distinct categories – ranging from UltraLow Risk, Low Risk, High Risk 1, and High Risk 2– to fuel a right-sized care plan tailored to each woman’s tumor biology and her life’s plans.